These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 24224771)
1. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine. Moreaux J; Bruyer A; Veyrune JL; Goldschmidt H; Hose D; Klein B Br J Haematol; 2014 Feb; 164(4):613-6. PubMed ID: 24224771 [No Abstract] [Full Text] [Related]
2. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors. Moreaux J; Rème T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B Mol Cancer Ther; 2012 Dec; 11(12):2685-92. PubMed ID: 23087257 [TBL] [Abstract][Full Text] [Related]
3. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)]. Takahashi Y; Kimura S; Okano M Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323 [No Abstract] [Full Text] [Related]
4. Out of Africa and into epigenetics: discovering reprogramming drugs. Jones P Nat Cell Biol; 2011 Jan; 13(1):2. PubMed ID: 21173799 [No Abstract] [Full Text] [Related]
5. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Khong T; Sharkey J; Spencer A Haematologica; 2008 Jun; 93(6):860-9. PubMed ID: 18443271 [TBL] [Abstract][Full Text] [Related]
6. Azacitidine. Issa JP; Kantarjian HM; Kirkpatrick P Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567 [No Abstract] [Full Text] [Related]
7. Epigenetic silencing of miR-335 induces migration by targeting insulin-like growth factor-1 receptor in multiple myeloma. Qi J; Shi LY; Wu Y; Shen XJ; Yuan J; Jin CJ; Cong H; Ju SQ Leuk Lymphoma; 2019 Dec; 60(13):3188-3198. PubMed ID: 31190579 [TBL] [Abstract][Full Text] [Related]
8. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772 [TBL] [Abstract][Full Text] [Related]
9. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Lavelle D; DeSimone J; Hankewych M; Kousnetzova T; Chen YH Leuk Res; 2003 Nov; 27(11):999-1007. PubMed ID: 12859993 [TBL] [Abstract][Full Text] [Related]
10. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation. Grövdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellström-Lindberg E Leukemia; 2014 Feb; 28(2):411-3. PubMed ID: 24025691 [No Abstract] [Full Text] [Related]
11. Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation. Oka S; Ono K; Nohgawa M Ann Hematol; 2017 Aug; 96(8):1411-1413. PubMed ID: 28577044 [No Abstract] [Full Text] [Related]
12. Digging deep into "dirty" drugs - modulation of the methylation machinery. Pleyer L; Greil R Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693 [TBL] [Abstract][Full Text] [Related]
13. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma. Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765 [No Abstract] [Full Text] [Related]
14. Epigenetic silencing of LPP/miR-28 in multiple myeloma. Li Z; Wong KY; Chan GC; Chim CS J Clin Pathol; 2018 Mar; 71(3):253-258. PubMed ID: 28775176 [TBL] [Abstract][Full Text] [Related]
15. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295 [TBL] [Abstract][Full Text] [Related]
16. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654 [No Abstract] [Full Text] [Related]
17. Azacitidine and the beginnings of therapeutic epigenetic modulation. O'Dwyer K; Maslak P Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapies move into new territory, but how exactly do they work? Tuma RS J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677 [No Abstract] [Full Text] [Related]
19. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. Chim CS; Liang R; Fung TK; Choi CL; Kwong YL J Clin Pathol; 2007 Jun; 60(6):664-9. PubMed ID: 17557868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]